Tiara is a novel transcatheter device that will enable the treatment of mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.
Neovasc is in the pre-clinical stage of developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.
The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart. Due to the complexity of the mitral valve anatomy, development of transcatheter treatments for mitral regurgitation has significantly lacked in comparison to aortic valve replacement devices.
Challenges to treatment of the mitral valve include:
- Complex geometry of the mitral apparatus
- Conformational changes of the mitral apparatus throughout the cardiac cycle
- Maintaining continuity with the sub valvular structures
- Native D shape of the mitral valve
- Proximity to the aortic valve and potential for LVOT obstruction
- Large size of the mitral valve – larger crossing profile
- High closing pressures
- Left ventricular remodelling
Tiara has been designed specifically to address each of these challenges and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation typically takes 5-10 minutes via a trans-apical approach and does not require any hemodynamic support or rapid pacing.
We invite you to register for Neovasc news alerts to be apprised of Tiara updates as we move through the development program.